172 related articles for article (PubMed ID: 21867960)
1. MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis.
Wo X; Han D; Sun H; Liu Y; Meng X; Bai J; Chen F; Yu Y; Jin Y; Fu S
J Genet Genomics; 2011 Aug; 38(8):341-50. PubMed ID: 21867960
[TBL] [Abstract][Full Text] [Related]
2. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
Wan Y; Wu W; Yin Z; Guan P; Zhou B
BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
[TBL] [Abstract][Full Text] [Related]
3. MDM2 SNP309 polymorphism and colorectal cancer risk: a meta-analysis.
Cao X; Zhang T; Zhao Z; Zhao T
DNA Cell Biol; 2012 Mar; 31(3):355-9. PubMed ID: 21770737
[TBL] [Abstract][Full Text] [Related]
4. Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis.
Bai J; Dai J; Yu H; Shen H; Chen F
J Toxicol Environ Health A; 2009; 72(11-12):677-82. PubMed ID: 19492228
[TBL] [Abstract][Full Text] [Related]
5. Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis.
Ma HB; Huang T; Han F; Chen WY
Asian Pac J Cancer Prev; 2012; 13(6):2841-6. PubMed ID: 22938470
[TBL] [Abstract][Full Text] [Related]
6. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies.
Hu Z; Jin G; Wang L; Chen F; Wang X; Shen H
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2717-23. PubMed ID: 18086778
[TBL] [Abstract][Full Text] [Related]
7. MDM2 SNP309T>G polymorphism with hepatocellular carcinoma risk: a meta-analysis.
Liu GY; Jiang DK; Shen SQ; Yu L
Arch Med Res; 2011 Feb; 42(2):149-55. PubMed ID: 21565629
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis.
Economopoulos KP; Sergentanis TN
Breast Cancer Res Treat; 2010 Feb; 120(1):211-6. PubMed ID: 19590949
[TBL] [Abstract][Full Text] [Related]
9. The MDM2 309 T/G polymorphism is associated with head and neck cancer risk especially in nasopharyngeal cancer: a meta-analysis.
Zhang Y; Bai Y; Zhang Y; Guan J; Chen L
Onkologie; 2012; 35(11):666-70. PubMed ID: 23147543
[TBL] [Abstract][Full Text] [Related]
10. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
11. MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis.
Peng Q; Mo C; Qin A; Lao X; Chen Z; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
J Exp Clin Cancer Res; 2013 Nov; 32(1):85. PubMed ID: 24423195
[TBL] [Abstract][Full Text] [Related]
12. Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis.
Ding H; Dai Y; Ning Z; Fan N; Wang Z; Li P; Zhang L; Tao Y; Wang H
Medicine (Baltimore); 2016 Mar; 95(12):e2941. PubMed ID: 27015167
[TBL] [Abstract][Full Text] [Related]
13. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
Li Y; Zhao H; Sun L; Huang L; Yang Q; Kong B
Hum Cell; 2011 Jun; 24(2):57-64. PubMed ID: 21547352
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis.
Zhao E; Cui D; Yuan L; Lu W
Mol Biol Rep; 2012 Apr; 39(4):3471-7. PubMed ID: 21725850
[TBL] [Abstract][Full Text] [Related]
15. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
16. Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.
Leu JD; Wang CY; Tsai HY; Lin IF; Chen RC; Lee YJ
Oncol Rep; 2011 Jun; 25(6):1755-63. PubMed ID: 21479369
[TBL] [Abstract][Full Text] [Related]
17. MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis.
Ma Y; Bian J; Cao H
PLoS One; 2013; 8(2):e56918. PubMed ID: 23451111
[TBL] [Abstract][Full Text] [Related]
18. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
19. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.
Sun YF; Leu JD; Chen SM; Lin IF; Lee YJ
BMC Cancer; 2009 Jan; 9():13. PubMed ID: 19144119
[TBL] [Abstract][Full Text] [Related]
20. An updated meta-analysis on the association of MDM2 SNP309 polymorphism with colorectal cancer risk.
Qin X; Peng Q; Tang W; Lao X; Chen Z; Lai H; Deng Y; Mo C; Sui J; Wu J; Zhai L; Yang S; Li S; Zhao J
PLoS One; 2013; 8(9):e76031. PubMed ID: 24098760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
